Holen Sie sich die Stockscreener-App
333.87
2.73%
8.87
Handel nachbörslich:
333.50
-0.37
-0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$325.00
Offen:
$325.6
24-Stunden-Volumen:
1.37M
Relative Volume:
0.79
Marktkapitalisierung:
$64.96B
Einnahmen:
$328.68B
Nettoeinkommen (Verlust:
$2.55B
KGV:
25.61
EPS:
13.0349
Netto-Cashflow:
$1.56B
1W Leistung:
+9.01%
1M Leistung:
+10.03%
6M Leistung:
-8.70%
1J Leistung:
+14.85%
1-Tages-Spanne:
$324.30
$333.95
1-Wochen-Bereich:
$311.00
$333.95
52-Wochen-Spanne:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
333.87 | 60.54B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
901.77 | 99.52B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
240.26 | 53.72B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
89.18 | 9.64B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.39 | 1.25B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
COR|Cencora Inc|Price:311.235|Chg%:+1.345 - TradingKey
Cencora Inc (COR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cencora Inc (COR) Cash Flow - TradingKey
Cencora, Inc. (COR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Cencora (COR) Q2 2026 Earnings Call Transcript - Fortune
Cencora, Inc. (COR) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
How Cencora’s Valuation Re‑Rating At Cencora (COR) Has Changed Its Investment Story - simplywall.st
Is Cencora (COR) Still Trading At A Discount As Its P E Rerating Gains Pace? - Yahoo Finance
Cencora, Inc. (COR) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Cencora, Inc. (COR) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Cencora, Inc. (COR) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Cencora Inc (COR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cencora Inc (COR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cencora, Inc. (COR) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Cencora (COR) Stock Could Be 39% Below Fair Value - simplywall.st
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
A4EQAC Bond Risk Profile - TradingView
Here's Why You Should Add Cencora Stock to Your Portfolio Now - TradingView
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Yahoo Finance
COR|Cencora Inc|Price:310.184|Chg%:+0.294 - TradingKey
Cencora stock holds steady as investors await fresh numbers - AD HOC NEWS
Cencora Inc (COR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cencora, Inc. (0HF3) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Cencora, Inc. (0HF3) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Cencora stock trades steady as specialty distribution scale and recent earnings shape investor view - AD HOC NEWS
COR stock consolidates after strong fiscal 2025 results and guidance update - Ad-hoc-news.de
Cencora: Specialty Infrastructure Is Rewriting The Distributor Model (NYSE:COR) - Seeking Alpha
Cencora earnings preview: What to expect - MSN
ABC5953643 Bond Risk Profile - TradingView
Cencora stock trades steadily as pharmaceuticals distributor highlights rising revenue and earnings - Ad-hoc-news.de
Cencora, Inc. Stock 12‑Month Price Target Raised to $354.58, Implies 17% Upside - TradingView
ETFs Investing in Cencora, Inc. Stocks - TradingView
Cencora stock trades near record levels as earnings and guidance underpin healthcare distribution gr - Ad-hoc-news.de
Cencora Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cencora stock holds firm as revenue and profit trends stay in focus - Ad-hoc-news.de
US3073EBC8 Bond Risk Profile - TradingView
Cencora stock trades near record levels as specialty distribution growth supports earnings - AD HOC NEWS
Steve Collis: Pharmaceutical Distribution Leader and Former Chairman, President, and CEO of Cencora - BBN Times
Cencora stock holds after fiscal 2026 growth update - ad-hoc-news.de
Cencora stock trades steadily as recent earnings highlight solid revenue growth - ad-hoc-news.de
XS3071246378 Bond Risk Profile - TradingView
XS3071246378 Bond Coupon Profile — Rate & Payments - TradingView
ABC6310083 Bond Coupon Profile — Rate & Payments - TradingView
XS3071246378 Bond Profile — Key Metrics - TradingView
Cencora stock trades steadily as specialty distribution growth supports earnings - Ad-hoc-news.de
Fund Update: 235,570 CENCORA (COR) shares added to FORT WASHINGTON INVESTMENT ADVISORS INC |OH| portfolio - Quiver Quantitative
Cencora Earnings Preview: What to Expect - inkl
A1ZW87 Bond Coupon Profile — Rate & Payments - TradingView
Lobbying Update: $60,000 of CENCORA INC. lobbying was just disclosed - Quiver Quantitative
ABC6310086 Bond Profile — Key Metrics - TradingView
Is Cencora Inc (COR) Overvalued After 3.9% Rally? GF Value Says - GuruFocus
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cencora Inc-Aktie (COR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tyler Lauren M | Director |
Jun 22 '26 |
Buy |
270.23 |
550 |
148,626 |
4,359 |
| DURCAN DERMOT MARK | Director |
Jun 18 '26 |
Buy |
274.19 |
4,000 |
1,096,760 |
31,767 |
| DURCAN DERMOT MARK | Director |
May 28 '26 |
Buy |
266.26 |
4,000 |
1,065,040 |
27,767 |
| Battaglia Silvana | Executive Vice President |
Mar 11 '26 |
Option Exercise |
0.00 |
8,415 |
0 |
27,239 |
| Campbell Elizabeth S | Executive Vice President |
Mar 11 '26 |
Option Exercise |
0.00 |
12,623 |
0 |
36,548 |
| Cleary James F | Chief Financial Officer |
Mar 11 '26 |
Option Exercise |
0.00 |
12,623 |
0 |
165,766 |
| Mauch Robert P. | President & CEO |
Feb 20 '26 |
Option Exercise |
86.09 |
3,762 |
323,871 |
69,155 |
| Mauch Robert P. | President & CEO |
Feb 20 '26 |
Sale |
358.94 |
3,762 |
1,350,332 |
65,393 |
| Mauch Robert P. | President & CEO |
Feb 18 '26 |
Sale |
359.46 |
1,333 |
479,160 |
65,393 |
1.30%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):